Synthesis path of Timisatem
A technology of telmisartan and synthetic method, which is applied in the fields of drug combination, cardiovascular system diseases, organic chemistry, etc., can solve the problems of reduced yield, unfavorable large-scale industrial production, and many impurities, and achieve high yield and product quality Improved effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0017] Example 1 4'-[(1,4'-dimethyl-2'-propyl[2,6'-di-1H-benzimidazol]-1'yl)methyl]-[1,1' -Biphenyl]-2-Carboxylic acid methyl ester (IVa)
[0018] I (30.4g, 0.10mol), methyl 4'-bromomethylbiphenyl-2-carboxylate (32.0g, 0.105mol), K 2 CO 3 Fine powder (or other inorganic bases as mentioned above) (41.4 g, 0.3 mol) was mixed with DMF (or other solvents as mentioned above) (600 ml), and reacted at room temperature (20-30° C.) for 10 hours. The reaction solution was poured into ice water (1000g), extracted with ethyl acetate (500ml×3), the organic phases were combined, washed with water (500ml×2), and washed with saturated brine (500ml). After drying over anhydrous sodium sulfate, it was concentrated under reduced pressure to a small volume, and petroleum ether was added dropwise with stirring until solids were precipitated. Crude IVa was obtained (42.9 g, 81.3%). It can be directly used in the next reaction without purification. The analytical sample was recrystallized from ...
Embodiment 2
[0019] Example 2 4'-[(1,4'-dimethyl-2'-propyl[2,6'-di-1H-benzimidazol]-1'-yl)methyl]-[1,1 '-Biphenyl]-2-carboxylic acid methyl ester (IVa)
[0020] I (30.4g, 0.10mol), methyl 4'-bromomethylbiphenyl-2-carboxylate (32.0g, 0.105mol), sodium ethoxide (or other organic bases as previously described) (20.4g, 0.3 mol) was mixed with dry DMF (or other solvents as mentioned above) (500ml), and reacted at 60°C for 8 hours. Aftertreatment is with embodiment 1.
Embodiment 3
[0021] Example 3 4'-[(1,4'-dimethyl-2'-propyl[2,6'-di-1H-benzimidazol]-1'-yl)methyl]-[1,1 '-biphenyl]-2-carboxylic acid (III)
[0022] Take IVa (26.4g, 0.05mol) obtained in the previous step, mix with glacial acetic acid (150ml) and concentrated hydrochloric acid (150ml) (or other acids as mentioned above), and react at 100°C for 5 hours. Concentrate under reduced pressure to remove most of the mixed acid, and the residue is slowly poured into ice (500g), cooled with cold saturated K 2 CO 3 The pH of the aqueous solution was adjusted to neutral, and the precipitate was filtered out and washed with water to obtain crude product III, which was recrystallized from DMF to obtain III (20.1 g, 78.4%, HPLC>99.0%). mp 261-263°C. 1HNMR (CDCl 3 ): 1.05 (3H,t,CH 2 CH 3 ), 1.88 (2H, m, CH 2 CH 2 CH 3 ), 2.79 (3H, s, ArCH 3 ), 2.92 (2H, t, CH 2 CH 2 CH 3 ), 3.86 (3H, s, NCH 3 ), 5.44 (2H, s, ArCH 2), 7.17-7.82 (14H, m, ArH). MS (EI) m / z: 515 (M+1), 469 (base peak), 442, 30...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com